Application of ACSL6 in the treatment of liver cancer

By detecting and inhibiting the ACSL6 expression level in liver cancer cells, the effect of anti-PD-1 antibody treatment is improved, and the problem of poor response to immunotherapy in patients with liver cancer is solved, and new therapeutic targets and prognosis evaluation methods are provided, which significantly improves liver cancer. Patient survival and treatment effect.

CN118403167BActive Publication Date: 2024-12-03THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410394054.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-02
Publication Date
2024-12-03
Estimated Expiration
2044-04-02

AI Technical Summary

Technical Problem

Patients with liver cancer have poor response to immunotherapy, resulting in inefficient treatment. The prior art is difficult to effectively inhibit the molecular mechanism of immunotherapy, affecting the prognosis.

Method used

By detecting the expression level of ACSL6 in liver cancer cells, ACSL6 inhibitors are developed to increase the sensitivity to anti-PD-1 antibody treatment and used in combination with anti-PD-1 antibodies, providing pharmaceutical compositions and detection reagents for the treatment of liver cancer.

Benefits of technology

It significantly improves the sensitivity of liver cancer to anti-PD-1 antibody treatment, improves the prognosis of liver cancer patients, provides scientific basis for treatment plans, provides new drug targets, and has important social value and market prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118403167B_ABST
    Figure CN118403167B_ABST
Patent Text Reader

Abstract

The present invention relates to the application of ACSL6 in the treatment of liver cancer. The present invention discovers for the first time the biomarker ACSL6 related to immunotherapy of liver cancer and prediction of patient prognosis. The prognosis of liver cancer patients is judged by detecting the expression level of ACSL6 in liver cancer tissues, and the efficiency of immune checkpoint treatment is improved by targeting ACSL6, thereby improving the prognosis of liver cancer patients. The present invention found through clinical liver cancer samples and a series of in vitro and in vivo functional experiments that the expression level of ACSL6 is significantly increased in liver cancer tissues, and its high expression is positively correlated with the poor prognosis of liver cancer patients; ACSL6 expression in liver cancer patient tissues is negatively correlated with CD8A expression. By targeting ACSL6 and combining anti-PD-1 antibodies to treat liver cancer, the efficiency of liver cancer treatment can be improved and the survival period can be prolonged. The present invention provides effective support for immunotherapy of liver cancer and has significant clinical significance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine and relates to the application of ACSL6 in the treatment of liver cancer. Background Art

[0002] At present, there are many clinical treatments for liver cancer patients, such as surgical resection, liver transplantation and comprehensive treatment, but due to its high recurrence rate and metastasis rate, the overall survival rate of liver cancer patients is still not optimistic. With the application and development of medical technology in recent years, the survival of liver cancer patients has improved, but the overall survival rate and prognosis of liver cancer patients are still not ideal. Since 2020, atezolizumab (anti-PD-L1 antibody) combined with bevacizumab (anti-VEGF antibody) has become the first-line treatment for patients with advanced liver cancer, significantly improving the survival of liver cancer patients. However, clinical findings show that only 20-30% of patients respond to immunotherapy, and multiple factors lead to low efficiency of immunotherapy, and the formation of an immunosuppressive microenvironment is the most important reason. Therefore, there is an urgent need to find molecules that inhibit immunotherapy during the development of liver cancer, clarify the potential inhibitory mechanism, develop more effective immunotherapy methods, and improve the prognosis of liver cancer patients. Summary of the invention

[0003] The purpose of the present invention is to solve the problems of poor immunotherapy response and low treatment efficiency in liver cancer patients in the prior art, and thus conduct in-depth research on the occurrence and development mechanism of liver cancer, clarify that ACSL6 is an important target related to liver cancer, and the resistance to immune checkpoint inhibitors and prognosis of liver cancer patients can be determined by detecting the expression level of ACSL6 in liver cancer cells, and the sensitivity of liver cancer to treatments such as anti-PD-1 antibodies can be increased by inhibiting the expression of ACSL6, providing a scientific basis for the formulation of subsequent treatment plans and prognosis evaluation.

[0004] In order to solve the above technical problems, the present invention is implemented through the following technical solutions.

[0005] The first aspect of the present invention provides the use of an ACSL6 inhibitor in the preparation of a drug for improving the therapeutic sensitivity and / or therapeutic effect of an anti-PD-1 antibody on liver cancer.

[0006] Preferably, the ACSL6 inhibitor is selected from one or more of shRNA, sgRNA, and siRNA designed based on ACSL6.

[0007] Preferably, the ACSL6 inhibitor is selected from shRNA designed based on ACSL6, and the sequence of the shRNA designed based on ACSL6 is selected from one or more of SEQ ID NO: 1 and SEQ ID NO: 2.

[0008] A second aspect of the present invention provides a pharmaceutical composition for treating liver cancer, comprising an ACSL6 inhibitor and an anti-PD-1 antibody, and pharmaceutically acceptable excipients.

[0009] Preferably, the ACSL6 inhibitor is selected from one or more of shRNA, sg RNA, and siRNA designed based on ACSL6.

[0010] Preferably, the ACSL6 inhibitor is selected from shRNA designed based on ACSL6, and the sequence of the shRNA designed based on ACSL6 is selected from one or more of SEQ ID NO: 1 and SEQ ID NO: 2.

[0011] Preferably, the pharmaceutically acceptable excipient is selected from one or more of a filler, a disintegrant, a binder, a lubricant, a flavoring agent, a preservative, an antioxidant, and a colorant.

[0012] The third aspect of the present invention provides the use of an ACSL6 inhibitor in the preparation of a drug for treating liver cancer.

[0013] Preferably, the ACSL6 inhibitor is selected from one or more of shRNA, sgRNA, and siRNA designed based on ACSL6.

[0014] Preferably, the ACSL6 inhibitor is selected from shRNA designed based on ACSL6, and the sequence of the shRNA designed based on ACSL6 is selected from one or more of SEQ ID NO: 1 and SEQ ID NO: 2.

[0015] A fourth aspect of the present invention provides the use of a reagent for detecting the expression level of ACSL6 in the preparation of a composition for predicting the therapeutic efficacy and / or evaluating the prognosis of liver cancer.

[0016] Preferably, the reagent for detecting the expression level of ACSL6 includes primers for detecting the expression level of ACSL6 gene and / or a reagent for detecting the expression level of ACSL6 protein.

[0017] Preferably, the efficacy prediction is specifically the efficacy prediction of anti-PD-1 antibodies.

[0018] Preferably, the primers for detecting the expression level of ACSL6 gene are selected from the following primer pair: the upstream primer sequence of the primer pair is shown in SEQ ID NO: 3, and the downstream primer sequence is shown in SEQ ID NO: 4.

[0019] Preferably, the reagent for detecting the expression level of ACSL6 protein is selected from ACSL6 monoclonal antibody and / or ACSL6 polyclonal antibody.

[0020] Preferably, the anti-ACSL6 antibody for detecting the expression level of ACSL6 protein can be selected from one or more of NBP1-89269 (Novus Biologicals), PA5-101652 (Ther mo Fisher Scientific), and ab229958 (abcam).

[0021] The fifth aspect of the present invention provides a kit for predicting the therapeutic efficacy and / or evaluating the prognosis of liver cancer, comprising a reagent for detecting the expression level of ACSL6; and one or more of PCR enzyme, PCR buffer, dNTPs, and fluorescent substrate.

[0022] Preferably, the reagent for detecting the expression level of ACSL6 includes primers for detecting the expression level of ACSL6 gene and / or a reagent for detecting the expression level of ACSL6 protein.

[0023] Preferably, the efficacy prediction is specifically the efficacy prediction of anti-PD-1 antibodies.

[0024] Preferably, the primers for detecting the expression level of ACSL6 gene are selected from the following primer pair: the upstream primer sequence of the primer pair is shown in SEQ ID NO: 3, and the downstream primer sequence is shown in SEQ ID NO: 4.

[0025] Preferably, the reagent for detecting the expression level of ACSL6 protein is selected from ACSL6 monoclonal antibody and / or ACSL6 polyclonal antibody.

[0026] Preferably, the anti-ACSL6 antibody for detecting the expression level of ACSL6 protein can be selected from one or more of NBP1-89269 (Novus Biologicals), PA5-101652 (Ther mo Fisher Scientific), and ab229958 (abcam).

[0027] Preferably, the fluorescent substrate is selected from Syber Green or a fluorescently labeled probe.

[0028] It should be understood that, unless otherwise specified, in the context of the present invention, the ACSL6 inhibitor refers to a substance that can specifically downregulate the expression level of ACSL6 and / or the transcription level of its mature mRNA and / or the expression level or activity of ACSL6 protein, for example, antisense oligonucleotides, siRNA, shRNA, sgRNA, antagomiRs, miRNA sponges, miRNA Erasers, Target Masking and / or multi-target methods are used to downregulate the expression level and / or activity of ACSL6, as long as the level and / or activity of ACSL6 can be reduced. The primers and / or primer pairs refer to PCR primers used to synthesize the cDNA chain of the ACSL6 gene in PCR, so as to detect the expression level of the ACSL6 gene mRNA. In addition to the primers and / or primer pairs listed in the present invention, those skilled in the art are fully capable of designing corresponding primers and / or primer pairs based on the gene sequence of ACSL6 using conventional methods in the field including but not limited to molecular biology, and screening the designed primers and / or primer pairs by conventional experimental means, as long as they can achieve specific detection of ACSL6 expression levels; conventional antibodies in the field can also be used to detect ACSL6 protein expression levels.

[0029] Compared with the prior art, the present invention has the following technical effects:

[0030] (1) The present invention uses clinical liver cancer samples and a series of in vitro and in vivo functional experiments to find that the expression level of ACSL6 is significantly increased in liver cancer tissues, and its high expression is positively correlated with the poor prognosis of liver cancer patients; high expression of ACSL6 significantly promotes the growth and metastasis of liver cancer cells, which can be used to predict the treatment effect and prognosis of liver cancer, and provide an early evaluation for patients to receive preoperative treatment plans.

[0031] (2) The present invention reveals through a series of in vivo and in vitro experiments that ACSL6 can promote the expression of immunosuppressive factors and reduce the therapeutic efficiency of immune checkpoint inhibitors. By targeting ACSL6, liver cancer proliferation and metastasis are inhibited, and the immunotherapy effect is improved, providing effective support for the diagnosis and treatment of liver cancer. The present invention has important practical significance for achieving precision treatment by revealing the correlation between ACSL6 and liver cancer treatment. It provides a new drug treatment target for humans to conquer liver cancer, thereby providing a new direction for subsequent drug development, clinical treatment, etc., and has extremely high social value and market application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 Schematic diagram of the results of WB detection of ACSL6 expression levels in liver cancer tissues and adjacent tissues.

[0033] Figure 2Schematic diagram of the results of qPCR detection of ACSL6 expression levels in liver cancer tissues and adjacent tissues.

[0034] Figure 3 Schematic diagram of the results of immunohistochemistry detection of ACSL6 expression levels in liver cancer tissues and paired non-cancerous tissues.

[0035] Figure 4 This is a schematic diagram of the effect of ACSL6 expression level on the survival of liver cancer patients.

[0036] Figure 5 Schematic diagram of the effect of ACSL6 on the proliferation of liver cancer cells.

[0037] Figure 6 Schematic diagram of Transwell results.

[0038] Figure 7 Schematic diagram of the effect of ACSL6 expression level on tumor growth in vivo.

[0039] Figure 8 Schematic diagram of the results of studying the effect of ACSL6 expression level on liver cancer metastasis in the tail vein metastasis model.

[0040] Fig. 9 GSEA enrichment analysis of RNA-seq data for ACSL6 knockdown.

[0041] Fig.10 This is a schematic diagram of the effect of ACSL6 expression level on the expression level of immune-related genes.

[0042] Fig.11 Schematic diagram of the results of immunohistochemistry detection of ACSL6 and CD8A expression levels in liver cancer tissues.

[0043] Fig.12 Schematic diagram of the results of testing the effect of ACSL6 on the development of liver cancer in the mouse hydrodynamic liver cancer model.

[0044] Fig.13 Schematic diagram of the effect of ACSL6 on the therapeutic activity of anti-PD-1 antibodies. DETAILED DESCRIPTION

[0045] In order to make the purpose, technical scheme and effect of the present invention clearer and more specific, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0046] Unless otherwise specified, the cell lines listed in the context of the present invention, including 293T, M HCC97H, Huh7, Hepa1-6, HepG2, etc., are cultured according to the prior art, and all cell lines are identified by short tandem repeat analysis of China Type Culture Collection (Wuhan), and the presence of mycoplasma contamination is verified using a PCR detection kit (Shanghai Biothrive Sci), and frozen in liquid nitrogen and used for subsequent experiments. The reagents used in the present invention are all commercially available. The experimental methods used in the present invention, such as nucleic acid extraction, whole genome sequencing, primer design, immunohistochemistry, Western blot, cell experiments, etc., are all conventional methods and techniques in the art. Representative results are selected from the biological experiment repetitions and presented in the context drawings, and the data are displayed as mean ± SD and mean ± SEM as specified in the diagram. All in vitro experiments were repeated at least three times, and animal experiments were repeated twice. The data were analyzed using GraphPad Prism 8.0 or SPSS22.0 software. Conventional medical statistical methods such as t-test, chi-square test, and analysis of variance were used to compare the mean differences of two or more groups. *p<0.05 was considered a significant difference.

[0047] Example 1

[0048] First, biopsy samples of liver cancer patients from the First Affiliated Hospital of Sun Yat-sen University were selected. The inclusion criteria for patients were as follows: (1) aged 18 years or older (including 18 years old), both males and females; (2) confirmed as liver cancer patients by histology or pathology (stages I-IV); (3) paraffin sections prepared from fresh tumor biopsy tissues; (4) expected survival period greater than or equal to 3 months. Western Blot was used to further verify the expression level of ACSL6 in liver cancer tissues and adjacent tissues. The specific steps are as follows:

[0049] (1) Hepatoma cells and normal cells were obtained from hepatoma tissues and paracancerous tissues, respectively. After culture, they were digested and collected into 1.5 mL EP tubes. The cells were washed twice with PBS, and cell lysis buffer containing 1× protease inhibitors and phosphatase inhibitors was added. The cells were placed on ice for 30 min. After cell lysis, the cells were collected into 1.5 mL EP tubes and centrifuged at 12,000 rpm and 4°C for 10 min.

[0050] (2) After protein quantification, add 5× protein loading buffer according to the sample volume, mix well, and incubate at 95°C in a water bath for 5 min.

[0051] (3) The protein sample obtained in step (2) was subjected to protein electrophoresis with the starting voltage set to 80 V. When the protein marker bands were clearly separated, the voltage was adjusted to 120 V.

[0052] (4) After protein electrophoresis, transfer can be performed. First, place the protein gel in the transfer solution for balance. Then add an appropriate amount of transfer solution into the container. Place the sponge, filter paper, PVD F membrane (activated with methanol), gel, filter paper, and sponge in order. Expel the gas and place the transfer tank in ice water. The transfer condition is 300 mA constant current for 1 hour.

[0053] (5) After the transfer is completed, place the membrane in 5% milk and block it on a shaker at room temperature for 1 hour.

[0054] (6) After blocking, wash the membrane once with 1× TBST buffer, cut the required bands, add the corresponding primary antibody, and place it on a shaker at 4°C overnight.

[0055] (7) Recover the primary antibody and wash the membrane three times with 1× TBST buffer, each time for 10 min.

[0056] (8) Incubate the secondary antibody at room temperature for 1 h, then wash the membrane three times with TBST buffer, 10 min each time.

[0057] (9) After washing the membrane, chemiluminescence can be performed. Prepare the ECL luminescence analyzer (A:B = 1:1) and use a Biorad chemiluminescence analyzer for luminescence development.

[0058] The experimental test results are as follows Figure 1 The results showed that the expression level of ACSL6 in liver cancer tissues of patients with liver cancer was significantly higher than that in normal tissues (***p<0.001).

[0059] Subsequently, qPCR was used to detect the expression level of ACSL6 in liver cancer tissues and adjacent tissues. The specific steps are as follows:

[0060] (1) After washing the cells with PBS, 2 Add 1 mL of RNA isolater to the cells in the culture area and evenly distribute it on the cell surface. Use a pipette to blow and hit the cells to remove them. Then transfer the lysate to a 1.5 mL centrifuge tube without RNase and beat it repeatedly with a pipette until it is fully lysed.

[0061] (2) Incubate on ice for 5 min, add 1 / 5 volume of chloroform, shake vigorously for 15 s to form an emulsion, and incubate at 4°C for 5 min.

[0062] (3) Centrifuge at 12,000 × g for 15 min at 4°C. Carefully transfer the aqueous phase to a new centrifuge tube. Add an equal volume of pre-cooled isopropanol, mix well, and incubate at 4°C for 10 min.

[0063] (4) Centrifuge at 4°C and 12,000 × g for 10 min, remove the supernatant, and use 1 mL of 75% ethanol (prepared with D EPC water) to flick the bottom of the tube to suspend the precipitate. Invert the tube several times and let it stand at room temperature for 3-5 min.

[0064] (5) Centrifuge at 4°C and 12,000 × g for 5 min, discard the supernatant, open the lid and dry the precipitate, add an appropriate amount of RNase-free ddH2O to dissolve the precipitate and detect the concentration. Use HiScript II reverse transcriptase (Vazyme #R201-01) to reverse transcribe the total RNA into cDNA, and remove genomic DNA at the same time. According to the measured RNA concentration, calculate the reaction system, as shown in Table 1 below.

[0065] Table 1 Reverse transcription reaction system

[0066]

[0067]

[0068] (6) cDNA was diluted at a ratio of 1:5 as a template, and qPCR was performed using ChamQ SYBR qPCR Master Mix (Vazyme #Q712) from Novagen. The 96 / 384-well fluorescence quantitative PCR instrument was Biorad. The reaction system configuration (taking a total volume of 20 μL as an example) was as follows: 2×Taq Pro Universal SYBR qPCR Master Mix 10 μL, upstream primer 0.4 μL, downstream primer 0.4 μL, cDNA 2 μL, ddH2O 7.2 μL; the primer sequences and amplification procedures used are shown in Tables 2 and 3, respectively.

[0069] Table 2 Primer sequences

[0070]

[0071] Table 3 qPCR amplification program

[0072]

[0073] Test results such as Figure 2 The results showed that, consistent with the results of WB analysis, the RNA expression level of ACSL6 in liver cancer cells was significantly higher than that in adjacent normal tissues (***p<0.001).

[0074] Furthermore, immunohistochemistry was used to detect the expression level of ACSL6 in tumor tissues and adjacent tissues. The specific steps are as follows:

[0075] (1) The biopsy sample tissue was embedded in paraffin for sealing. The paraffin specimen was stored at room temperature and the cut white slice was stored in a refrigerator at 4°C.

[0076] (2) During the experimental test, take out the paraffin sections and bake them in a 60°C oven for about 1 hour to allow the sections to adhere to the glass slide.

[0077] (3) Dewax the sections in two portions of xylene, each for 10 min.

[0078] (4) The sections were sequentially placed in gradient alcohol (100%, 100%, 95%, 85%, 70%) for hydration treatment, each time for 5-7 minutes, and then washed three times with PBS, each time for 3 minutes.

[0079] (5) Immerse the sections in citrate antigen retrieval solution and heat them in a microwave oven at medium-high temperature for 20 min for antigen retrieval. After heating, let the sections cool naturally to room temperature in the antigen retrieval solution and wash them three times with PBS for 3 min each time.

[0080] (6) Place the slices in a light-proof humidified box, cover the tissue with 3% hydrogen peroxide, and leave at room temperature for 30 minutes to completely remove endogenous peroxidase.

[0081] (7) Wash three times with PBS, 3 min each time. Add blocking solution and block at room temperature for 30 min to reduce nonspecific binding of the primary antibody.

[0082] (8) Shake off the blocking solution, add primary antibody to cover the tissue without washing, and place in a humidified box at 4°C for blocking overnight.

[0083] (9) The next day, the cells were placed at room temperature for 1 h, then washed with PBS for 5 min. This process was repeated three times.

[0084] (10) Add the reaction sensitization solution and incubate at room temperature for 20 min, then wash three times with PBS; add the biotin-labeled secondary antibody and incubate at room temperature for 30 min, then wash with PBS for 5 min, and repeat three times.

[0085] (11) DAB was added dropwise for color development, and after color development was complete, the reaction was terminated by placing the mixture in water.

[0086] (12) Add hematoxylin for 25-30 seconds for re-staining, and place in water to terminate the staining; then rinse in running water for 30-45 minutes until the color of the section stabilizes for anti-blueing treatment.

[0087] (13) Graded alcohol dehydration: Dehydrate the sections by immersing them in 70%, 85%, 95%, 100%, 100% alcohol, and xylene in sequence for 5 min each time, and then seal the sections.

[0088] Two independent researchers scored the clinical pathological immunohistochemical sections of the patients without knowing the patient information. The staining intensity was graded from 0 to 3: 0: all negative; 1: weak; 2: moderate; 3: strong. Four scores were assigned according to the percentage of positive cells: 0%-25% for 1 point; 26%-50% for 2 points; 51%-75% for 3 points; and above 75% for 4 points. Combining the staining intensity and the proportion score, the total score representing the ACSL6 content in the pathological tissue was obtained. The test results are as follows: Figure 3 The results showed that the expression level of ACSL6 in liver cancer tissues was significantly increased, which was consistent with the above protein and RNA analysis results.

[0089] The above experiments have shown that ACSL6 is highly expressed in liver cancer tissues and lowly expressed in normal tissues. In order to clarify the effect of ACSL6 on the survival rate of liver cancer patients, a follow-up analysis of liver cancer patients in the First Affiliated Hospital of Sun Yat-sen University after treatment found that patients can benefit significantly from low expression of ACSL6. The overall survival rate (OS) and progression-free survival (DFS) of patients with low expression of ACSL6 in liver cancer tissues are significantly higher than those of patients with high expression of ACSL6 (see Figure 4 ).

[0090] Example 2

[0091] In the above examples, the difference in the expression level of ACSL6 between liver cancer tissue cells and normal tissue cells and its effect on the survival rate of patients were clarified in clinical samples. In order to further study the role of ACSL6 in liver cancer, further research was conducted through a series of in vitro experiments.

[0092] First, shRNA was designed to reduce the expression level of ACSL6 in cells and its inhibitory activity was verified. The specific steps are as follows:

[0093] (1) Design shRNA knockdown sequences on the Sigma website, design primers based on the shRNA hairpin structure and synthesize primers, dilute the synthesized shRNA primers with water to 100 μM, take 10 μL of the upstream and downstream primers respectively, mix them evenly, and then use a PCR instrument to gradually cool down from 100° C. to room temperature to anneal and synthesize double strands; this embodiment uses two shRNAs as examples, namely shACSL6#1 (the sequence is shown in SEQ ID NO: 1, which is ccaggcaaacacaccattaaa) and shACSL6#2 (the sequence is shown in SEQ ID NO: 2, which is gcaggttaaagccatt cacat).

[0094] (2) The pLKO.1 lentiviral vector was double-digested with EcoRI and AgeI endonucleases, and two single bands were obtained by gel running after digestion. The larger band was cut out for gel recovery; then the annealed double-stranded DNA was ligated to the vector after gel recovery.

[0095] (3) 293T cells in the logarithmic growth phase were seeded in a 10 cm culture dish at a seeding density of about 70%; 6000 ng of the target plasmid loaded with shACSL6#1 or shACSL6#2, 4500 ng of PSP AX2, and 1500 ng of PMD2.G were transfected into the 293T cells and cultured for 48 h.

[0096] (4) After 48 hours, the culture medium was collected and the cell debris was filtered out using a 0.45 μm filter to obtain the virus solution.

[0097] (5) One day before infection, inoculate the hepatoma cells (MHCC97H, Huh7, Hepa1-6) in the logarithmic growth phase into a 6 cm culture dish, discard the original culture medium, add 3 mL of virus solution, and add 3 μL of polybrene to promote virus infection. After 24 hours, discard the virus solution and replace with fresh culture medium for continued culture.

[0098] (6) 48 hours after infection, the culture medium is discarded and a culture medium containing an appropriate concentration of puromycin is added. At this point, cells that have successfully integrated the exogenous gene have puromycin resistance and can survive. After continuous screening for 7 to 10 days, a stable cell line can be obtained, and the expression level of ACSL6 can be detected by qPCR or WB to determine whether the knockdown is successful.

[0099] The shRNA constructed above was then used to study the effect of differences in ACSL6 expression levels on the proliferation and migration of liver cancer cells. The specific steps of the cell proliferation experiment are as follows:

[0100] (1) Hepatoma cells (MHCC97H, Huh7) transfected with plasmids containing knockdown ACSL6 gene expression sequence (shACSL6#1) or blank control plasmids (shNT) in the logarithmic growth phase were digested with trypsin and counted. The appropriate cell density (1.0×10 3 / well) and inoculated into 96-well plates (3 replicates).

[0101] (2) The cells were cultured in a 37°C incubator and collected at 24 h, 48 h, 72 h, 96 h, and 120 h. 10 μL of CCK-8 was added to each well. The culture plate was incubated in the incubator for 1-4 h, and the absorbance at 450 nm was measured to evaluate the cell proliferation.

[0102] The experimental results are as follows Figure 5The results showed that after using shACSL6 to inhibit the expression of intracellular ACS L6, the proliferation activity of liver cancer cells could be significantly inhibited.

[0103] The specific steps of the Transwell experiment are as follows:

[0104] (1) 8-10×10 4 Hepatoma cells (MHCC97H, Huh7) in the logarithmic growth phase that were transfected with a plasmid that knocked down the ACSL6 gene expression sequence (shACSL6#1) or a blank control plasmid (shNT) were resuspended in serum-free culture medium and then inoculated in the upper chamber of a transwell chamber with a pore size of 8 μm, and 500-650 μL of culture medium containing fetal bovine serum was added to the lower chamber.

[0105] (2) After culturing for 24-48 hours, the culture medium was aspirated, 600 μL of 4% paraformaldehyde was added, and the cells were fixed for 30 minutes. The paraformaldehyde was discarded, and crystal violet was used for staining for 30 minutes.

[0106] (3) Use a cotton swab to wipe the non-migrated cells on the inner surface of the upper chamber; use an inverted optical microscope to obtain images, and use ImageJ software for analysis.

[0107] Test results such as Figure 6 The results showed that the migration ability of both MHCC97H cells and Huh7 cells could be significantly inhibited after treatment with the ACSL6 inhibitor shACSL6, and the difference was statistically significant compared with the control group without any treatment.

[0108] The above cell proliferation assay, clone formation assay, Trans well assay and wound healing assay were repeated using shACSL6#2, and the results were consistent with those of shACSL6#1 (not shown in the figure).

[0109] Further, the effect of ACSL6 on tumor growth in vivo was studied by the following steps:

[0110] (1) Six-week-old BALB / c nude mice were randomly divided into two groups, with six mice in each group. MHCC97H-shNT and MHCC97H-shACSL6 (shACSL6#1) cells were injected subcutaneously on the back of each mouse in each group at a dose of 2×10 6 Cells / piece.

[0111] (2) Six days after inoculation, the tumor volume was measured every three days. On day 28, the mice were euthanized, and the subcutaneous tumors were removed and weighed.

[0112] The experimental results are as follows Figure 7The results showed that the inhibition of intracellular ACSL6 expression levels could significantly reduce the growth rate and volume of tumors in vivo.

[0113] Subsequently, the effect of ACSL6 expression level on liver cancer metastasis was studied using the tail vein metastasis model. The specific steps are as follows:

[0114] (1) Six-week-old BALB / c nude mice were randomly divided into two groups, with six mice in each group. Each mouse in each group was injected with MHCC97H-shNT or MHCC97H-shACSL6 (shACSL 6#1) cells via the tail vein at a dose of 2×10 6 Cells / piece.

[0115] (2) 6-8 weeks after the tail vein injection, the mice were euthanized, and the lungs were removed, fixed with 4% paraformaldehyde (Biosharp Life Sciences, #BL539A), embedded in paraffin, and stained with H&E.

[0116] The experimental results are as follows Figure 8 The results showed that the inhibition of intracellular ACSL6 expression levels could significantly inhibit the metastasis of liver cancer cells.

[0117] Example 3

[0118] RNA-seq sequencing was performed on MHCC97H cells with ACSL6 knockdown and control in the above example, and GSEA analysis showed that the genes downregulated after ACSL6 knockdown were significantly enriched in NF-κB and inflammatory response pathways ( Fig. 9 ), which indicates that ACSL6 regulates these two pathways. Further, qPCR was used to detect the regulation of ACSL6 expression level on the expression level of genes related to NF-κB and inflammatory response pathways. The results are as follows Fig.10 As shown. The results showed that after the expression of ACSL6 in liver cancer cells was inhibited by sh RNA (shACL6#1), the expression of NF-κB target gene GADD45B and MMP3 proliferation and migration-related genes in the cells could be effectively reduced. In addition, it was found that after the expression of ACSL6 was inhibited, the expression levels of CXCL1 and CXCL5 immune-related genes were reduced, which suggested that ACSL6 may participate in the regulation of liver cancer immune microenvironment by regulating the NF-κB signaling pathway (*p<0.05, **p<0.01, ***p<0.001).

[0119] Next, the expression of ACSL6 and CD8A in liver cancer tissue samples was detected by immunohistochemistry according to the method in the above examples. The results showed that liver cancer tissues with high expression of ACSL6 were accompanied by low expression of CD8A ( Fig.11 ), indicating that ACSL6 may inhibit anti-tumor immune regulation.

[0120] Subsequently, the effect of ACSL6 expression level on liver cancer progression was studied using a hydrodynamic model. The specific steps are as follows:

[0121] (1) 20 μg of pT3-EF1αH-myr-AKT-HA, 20 μg of pT / Caggs-NR ASV12, and 1.6 μg of SB transposase (1 / 25 of the total plasmid) were diluted in 2 mL of saline, and the mixture was injected into the caudal vein of mice within 7 seconds to induce liver cancer.

[0122] (2) Two weeks after injection, six mice were randomly assigned to each group and then injected with AAV8-TBG-miR30-Acsl6-shRNA-GFP or AAV8-TBG-GFP-miR30-shRNA (1.5×10 per mouse) via the tail vein. 12 Four weeks after the injection of AAV, the mouse livers were collected to evaluate the effect of ACSL6 knockdown on HCC progression.

[0123] The results are as follows Fig.12 The results showed that inhibiting the expression level of ACSL6 in tumor cells can significantly inhibit the growth rate of tumors and increase the expression of CD8 + This suggests that ACSL6 can accelerate tumor growth by promoting the formation of a tumor suppressive microenvironment.

[0124] Furthermore, the effect of ACSL6 on the therapeutic effect of PD-1 antibody was studied through in vivo experiments. The specific steps are as follows:

[0125] (1) Six-week-old C57BL / 6J mice were randomly divided into four groups, designated as Group 1-4, with six mice in each group. Groups 1 and 3 were subcutaneously injected with 2×10 6 In groups 2 and 4, 2×10 Hepa1-6 cells expressing shNT were injected subcutaneously on the back. 6 Hepa1-6 cells expressing shRNA (shACSL6#1).

[0126] (2) Starting from the 15th day after inoculation, 200 μg of IgG isotype control antibody was intraperitoneally injected into mice in Group 1 and Group 2, and 200 μg of anti-PD-1 antibody (BioXcell) was intraperitoneally injected into mice in Group 3 and Group 4 twice a week; the tumor volume of mice in each group was regularly measured.

[0127] The experimental results are as follows Fig.13 The results showed that inhibiting the expression level of ACSL6 in tumor cells or using anti-PD-1 antibody treatment can inhibit the growth rate of tumors, prolong the survival time of mice, and increase the expression of CD8+ The number of T cells; after the combination of shACSL6 and anti-PD-1 antibody, the therapeutic activity of anti-PD-1 antibody against liver cancer can be significantly improved by inhibiting the expression of ACSL6, whether it is tumor growth rate, mouse survival time or in vivo CD8 + The number of cells was significantly improved compared to the treatment with either ACSL6 inhibition or anti-PD-1 antibody alone. This shows that by inhibiting the expression level of ACSL6 in liver cancer cells, the therapeutic effect of anti-PD-1 antibodies on liver cancer can be significantly improved, producing a synergistic therapeutic activity with them.

[0128] It can be clearly seen from the above that ACSL6 is a gene that is extremely relevant to liver cancer. The higher expression level of ACSL6 has a significant positive correlation with poor prognosis, and can be used to predict the treatment effect and prognosis of liver cancer. At the same time, ACSL6 has a key influence on the expression of immune-related genes in the body and the therapeutic activity of PD-1 antibodies. Accordingly, the expression level of ACSL6 in the body can be inhibited to improve the therapeutic effect of PD-1 antibodies on liver cancer. The present invention reveals the correlation between the ACSL 6 gene and the occurrence and development of liver cancer and PD-1 antibody treatment. It has important practical significance for solving the problem of clinical efficacy differences between individuals and the blank of regression effect / prognosis evaluation, and better realizing precision treatment. It provides a new drug treatment target for humans to conquer liver cancer, thereby providing a new direction for subsequent drug development, clinical treatment, etc., and has extremely high social value and market application prospects.

[0129] The above specific implementation method part specifically introduces the analytical method involved in the present invention. It should be noted that the above introduction is only to help those skilled in the art better understand the method and ideas of the present invention, rather than limiting the relevant content. Without departing from the principle of the present invention, those skilled in the art may also make appropriate adjustments or modifications to the present invention, and the above adjustments and modifications shall also fall within the scope of protection of the present invention.

Claims

1. Use of an ACSL6 inhibitor in the preparation of a drug for improving the sensitivity and / or therapeutic effect of anti-PD-1 antibodies on liver cancer treatment, characterized in that: The ACSL6 inhibitor is selected from shRNA designed based on ACSL6, and the sequence of the shRNA designed based on ACSL6 is selected from one or more of SEQ ID NO: 1 and SEQ ID NO:

2.

2. A pharmaceutical composition for treating liver cancer, characterized in that: It includes an ACSL6 inhibitor and an anti-PD-1 antibody, as well as pharmaceutically acceptable excipients; the ACSL6 inhibitor is selected from shRNA designed based on ACSL6, and the sequence of the shRNA designed based on ACSL6 is selected from one or more of SEQ ID NO: 1 and SEQ ID NO:

2.

3. Use of an ACSL6 inhibitor in the preparation of a drug for treating liver cancer, characterized in that: The ACSL6 inhibitor is selected from shRNA designed based on ACSL6, and the sequence of the shRNA designed based on ACSL6 is selected from one or more of SEQ ID NO: 1 and SEQ ID NO: 2.